GKOS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Glaukos Corporation

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
CEO
Thomas Burns
Employees
653
Headquarters

229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com

News

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
Sep 28, 2022 11:00am

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30 - October 3, 2022 in Chicago,


Source:Wallstreet:Online
Coupa Software, Glaukos rise; Occidental Petroleum falls
Sep 07, 2022 20:14pm

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday: EQT Corp., up 57 cents to $46. The natural gas company announced the purchase of gas and pipeline assets and doubled its stock buyback program. Coupa Software Inc., up $10 to $65.82. The software company reported strong second-quarter financial results. HealthEquity Inc., up 64 cents to $64.08. The provider of services for managing health care accounts raised its revenue forecast for the year. Occidental Petroleum Corp., down $1.45 to $65.43. Energy stocks slipped along with falling oil prices. Target Corp., up $7.21 to $170.79. The retailer is dropping the mandatory retirement age for its CEO, allowing Brian Cornell to stay on for three more years. United Parcel Service Inc., up 33 cents to $196.29. The package delivery service plans to hire more than 100,000 extra workers to help handle an increase in packages during the critical holiday season. Glaukos Corp., up $8.91 to $57.01. The drug developer gave investors an encouraging update on a potential glaucoma treatment.


Source:WNYT
Dow Jumps 450 Points; UiPath Shares Slide
Sep 07, 2022 18:42pm

U.S. stocks traded higher toward the end of trading, with the Dow Jones adding around 450 points on Wednesday. The Dow traded up 1.45% to 31,596.87 while the NASDAQ rose 1.99% to 11,774.77. The S&P 500 also rose, gaining, 1.74% to 3,976.30. Also check this: Fear & Greed Index Remains In ''Fear'' Zone As US Stocks Drop Leading and Lagging Sectors Utilities shares jumped by 2.6% on Tuesday. Meanwhile, top gainers in the sector included Azure Power Global Limited (NYSE: AZRE ), up 32% and Sunnova Energy International Inc. (NYSE: NOVA ) up 10%. In trading on Tuesday, energy shares fell by 1.5%. Top Headline The trade deficit narrowed by $10.2 billion to a nine-month low level of $70.7 billion in July. Exports from the US rose by 0.2% from the prior month to $259.3 billion, while imports fell 2.9% to $329.9 billion. Equities Trading UP Glaukos Corporation (NYSE: GKOS ) shares shot up 25% to $60.29 after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through 3 months in both Phase 3 trials and demonstrated excellent tolerability and a favorable safety …


Source:Benzinga
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
Sep 07, 2022 15:08pm

Glaukos Corporation (NYSE: GKOS ) gained 17.3% to $56.40 after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through 3 months in both Phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 12 months. Seres Therapeutics, Inc. (NASDAQ: MCRB ) gained 14.2% to $6.16. Seres Therapeutics announced completion of rolling BLA submission to the FDA … Full story available on Benzinga.com


Source:Benzinga
Glaukos (NYSE: GKOS) Shoots Up Following Positive Clinical Result
Sep 07, 2022 13:24pm

Glaukos Corp. (NYSE: GKOS) stock is surging on Wednesday as the pharmaceutical and ophthalmic medical technology announced positive topline data for both fast and slow release Phase 3 pivotal trials of iDose TR. iDose TR is the company''s novel formulation of travoprost, a drug used to reduce Intraocular pressure (IOP) in the treatment of open-angle glaucoma (OAG) or ocular hypertension. The positive topline data indicates that it offers a suitable alternative to daily eye drop treatment. Glaukos stated that the Phase 3 trials achieved the pre-specified primary efficacy endpoint for both the fast and slow release models of iDose TR through three months.


Source:TipRanks
Glaukos says pivotal trials for eye implant reached main goals
Sep 07, 2022 12:16pm

Glaukos Corporation (GKOS), a MedTech company focused on eye diseases, announced Wednesday that two pivotal Phase 3 trials for its eye implant iDose TR reached primary efficacy endpoints…


Source:Seeking Alpha
Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation
Aug 29, 2022 19:55pm


Source:Kwhen Finance
Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment
Aug 24, 2022 14:29pm

iVeena Delivery Systems Inc has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS ), granting an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the U.S. IVMED-80 … Full story available on Benzinga.com


Source:Benzinga